This symposium is organized by China Society, a student organization at the Harvard Kennedy School.
This panel will discuss the impact of China s health system structure (health financing, resource allocation, care organization, regulation) on China s COVID-19 response strategy and its resulting outcomes.
Panelists
Winnie Yip, Professor of the Practice of Global Health Policy and Economics at Harvard T.H. Chan School of Public Health, Director of the school-wide China Health Partnership
Ning Yi, Professor at Peking University School of Public Health
Zhang Yuntao, Vice President and Chief Scientist of China National Biotec Group (CNBG), a sinopharm subsidiary
Moderator: Leo Liu, MPA 2022
“On average, they don’t see the urgency. The number of cases is just not high and people have sort of returned to normal. Activities have resumed, so you can understand the desire for the vaccine is not very high,” said Winnie Yip, a professor of the practice in global health policy and economics at the Harvard T.H. Chan School of Public Health.
Vaccine hesitancy in Europe has been stoked by far-left and far-right parties, and lingering questions about the AstraZeneca shots and rare blood clots caused attitudes to darken in major countries, with only 23% of French respondents viewing that vaccine as safe in a recent poll.
Listen to the story.
A food delivery worker wearing a face mask prepares to place his customers orders at a collection point setup to help curb the spread of the coronavirus outside an office building in Beijing on Feb. 24, 2021. Credit:
Share
Countries across the globe are scrambling to vaccinate everyone. With 1.4 billion people, that’s a huge challenge for China. Their goal is to inoculate about 70% of its population which still hits the billion-dose range.
China is rolling out two of its own vaccines Sinopharm and Sinovac but it hasn’t been able to conduct trials on its own population because the coronavirus infection rates are so low.
A microbiologist in China examines blood samples as part of the malaria control program
December 16, 2020 – In 2010, China announced one of its most ambitious undertakings in public health: It planned to eliminate indigenous cases of malaria within a decade. The disease had a long and lethal history in the country it’s estimated that, in 1940, China had as many as 30 million cases of malaria resulting in 300,000 deaths and the parasite that causes it remained widespread in the early 2000s.
But by leveraging technology, implementing robust surveillance strategies, and firmly integrating the malaria control program into the country’s health system, China made quick work of one of the most persistent diseases on Earth. In 2016, the country recorded only three cases of indigenous malaria. In the years since, there hasn’t been a single documented case of malaria that originated within its borders. China is expected to soon be certified by the World Health Organization (WHO) as